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Infection of human cells by Human T-cell leukaemia
virus (HTLV-1) is mediated by the viral envelope glyco-
proteins. The gp46 surface glycoprotein binds to a cell
surface receptors, including heparan sulphate proteogly-
cans, neuropilin-1, and Glut-1, allowing the transmem-
brane glycoprotein to initiate fusion of the viral and
cellular membranes. The envelope glycoproteins are
recognised by neutralising antibodies and cytotoxic T
lymphocytes following a protective immune response,
and therefore represent attractive components for an
HTLV-1 vaccine. Here we begin to explore the immu-
nological properties of recombinant SU as a potential
subunit vaccine candidate. We have used a soluble
recombinant gp46 fused to the Fc-region of human IgG
(sRgp46-Fc) as an immunogen to vaccinate mice and
generate monoclonal antibodies (mAbs) targeting SU.
The recombinant SU protein is highly immunogenic,
inducing high titre antibody responses to the immuno-
gen and facilitating selection of hybridomas that secrete
anti-SU mAbs. Many of these mAbs recognise envelope
expressed by HTLV-1 infected cells and these antibodies
strongly stimulate neutrophil-mediated cytotoxic
responses. Moreover, several of the mAbs directly and
robustly antagonise envelope-mediated fusion and neu-
tralize pseudovirus infectivity. While antibodies targeting
either the receptor-binding domain or C-terminal
domain of SU exhibit anti-viral activity, the most
potently neutralizing mAbs tend to recognise epitopes
that cluster in the N-terminal receptor-binding domain
of SU. Thus, our data demonstrate that recombinant
forms of SU possess immunological features that are of
direct utility to subunit vaccine design.
Published: 6 June 2011
doi:10.1186/1742-4690-8-S1-A170
Cite this article as: Kuo et al.: Robust neutralising activity and activation
of neutrophil cytotoxic responses mediated by antibodies targeting the
HTLV-1 envelope glycoprotein. Retrovirology 2011 8(Suppl 1):A170.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
* Correspondence: d.w.brighty@dundee.ac.uk
The Biomedical Research Institute, College of Medicine Dentistry and
Nursing, Ninewells Hospital, Dundee, DD1 9SY, UK
Kuo et al. Retrovirology 2011, 8(Suppl 1):A170
http://www.retrovirology.com/content/8/S1/A170
© 2011 Kuo et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.